Anebulo Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel solutions for acute cannabinoid intoxication (“ACI”) and substance addiction, appointed Sandra Gardiner as the company’s acting chief financial officer. 

Gardiner joins Anebulo from Pulse Biosciences, Inc., where she served as chief financial officer until December 2022.  She brings more than 30 years of financial, operational and management experience, with demonstrated leadership and a strong network within the investor and financial analyst community.

Gardiner succeeds Rex Merchant, who served as the company’s chief financial officer since its inception and helped guide Anebulo through a successful IPO in May 2021.

“We are delighted to welcome Sandra to the Anebulo team given her strong financial experience and expertise within the biotech sector,” said Simon Allen, CEO of Anebulo. “Further, we have the opportunity to work with additional experts within Potrero Hill Advisors as needs arise, providing Anebulo with a flexible and fully integrated outsourced solution for our finance and accounting needs. We are especially grateful for the valuable contributions Rex made at Anebulo by helping transform the company into a publicly traded clinical stage biotech, and wish Rex every success in his future endeavors.”

Allen added: “I look forward to working with Sandra as we anticipate the release of our final Phase 2 study data before the end of this calendar quarter and prepare for an end of Phase 2A meeting with the FDA expected by the end of the second calendar quarter of 2023.”